Analgesic Ketamine for Battlefield Use
Closed Pre-Solicitation Posted
- Solicitation number
- HT9427-26-RFI-701
- Agency
- Not on record
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- Not on record
- PSC
- Not on record
- Place of performance
- Maryland 21702, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Defense's OPMED WPAC PMO is conducting market research to procure an analgesic ketamine product designed for Tactical Combat Casualty Care (TCCC) solutions addressing acute severe pain from battlefield injuries. The RFI is open to all interested vendors and encompasses ketamine products in multiple delivery formats, including autoinjectors, oral capsules, pumps, topical creams, and patches. Key objectives include developing, manufacturing, and obtaining FDA approval for a battlefield-suitable analgesic ketamine formulation. The government has indicated that evaluation criteria will focus on feasibility and industry capability to meet these development and regulatory requirements. The RFI was posted on December 11, 2025, with responses due by January 12, 2026, and the agency has already issued an amendment addressing RFI questions on December 16, 2025.
This opportunity carries no small business set-aside designation. The government anticipates a formal Request for Proposals in Fiscal Year 2026, with production requirements indicating a steady-state monthly volume of 26,722 units and surge capacity of 53,445 units per month over a 24-month period. The acquisition currently focuses on U.S. Department of War requirements, though vendors should anticipate potential NATO and allied nation purchasing alongside primary production needs. No current incumbent contractor is identified in the pre-solicitation notice. While specific budget figures are not disclosed in the pre-solicitation documents, the significant volume requirements and FDA approval pathway suggest a substantial procurement value and extended development timeline requiring substantial vendor resources and regulatory expertise.
Notice text
The purpose of this RFI is to address the OPMED WPAC PMO’s requirement for Tactical Combat Casualty Care (TCCC) solutions for acute severe pain from battlefield injuries. The OPMED WPAC PMO is conducting market research to determine the feasibility to collaborate with industry to develop, manufacturer, and receive U.S. Food and Drug Administration (FDA) approval of an analgesic ketamine product for procurement. All ketamine products for any route of administration will be considered, for example: autoinjectors, oral capsules, pumps, topical creams and patches, etc. OPMED WPAC PMO plans to release a request for proposals for the analgesic ketamine product in Fiscal Year 2026.
Please see list of attachments for other instructions.
Files
| File | Type | Posted |
|---|---|---|
| Amendment-RFI Questions Answered.docx | DOCX document | |
| B01-Analgesic-Ketamine-RFI-20251208-Final.docx | DOCX document |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity